Exclusive Summary

• Robust demand: Affecting over 64 million global patients with schizophrenia and bipolar disorder, it acts as a long-term maintenance staple with ultra-high recurring consumption.
• Clinical necessity: Proudly listed on the WHO Essential Medicines List, it is universally recognized as a first-line atypical antipsychotic by international guidelines like NICE and APA.
• Tendering edge: Driven by China's hyper-efficient supply chain, its massive cost advantage makes it an aggressive weapon to win public procurements and MOH tenders in emerging markets.
• Fast commercialization: Readily available in 5mg and 10mg mainstream strengths alongside comprehensive CTD dossiers, enabling distributors to achieve swift local registration and monetization.